Cited 7 times in
Impact of preoperative fibrinogen concentration on postoperative outcome in patients who received dual antiplatelet therapy in proximity to off-pump coronary bypass surgery
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 곽영란 | - |
dc.contributor.author | 김나영 | - |
dc.contributor.author | 송종욱 | - |
dc.contributor.author | 심재광 | - |
dc.date.accessioned | 2015-01-06T16:53:04Z | - |
dc.date.available | 2015-01-06T16:53:04Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1346-9843 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/98954 | - |
dc.description.abstract | Background: Preoperative fibrinogen concentration is associated with increased blood loss at the lower end, and with hypercoagulability-related ischemic event at the higher end in cardiac patients. We evaluated the influence of preoperative fibrinogen concentration on blood loss and outcome in patients who received clopidogrel in proximity to off-pump coronary artery bypass surgery (OPCAB). Methods and Results: Medical records of 538 patients who received clopidogrel within 5 days of OPCAB (April 2007 to March 2012) were retrospectively reviewed. Perioperative bleeding and composite of morbidity endpoints including myocardial infarction were compared in relation to the tertile distribution of the fibrinogen concentration. The amount of blood loss was significantly larger in the first tertile, whereas the incidence of composite of morbidity endpoints was significantly higher in the third tertile. In multivariate analysis for risk factors of perioperative blood loss, body mass index and duration of surgery were identified as independent risk factors but not the fibrinogen level. And hypertension and preoperative fibrinogen level were identified as independent risk factors about composite of morbidity. The third tertile was associated with a 2-fold increased risk of developing composite of morbidity endpoints. Conclusions: In patients who received dual antiplatelet therapy in proximity to OPCAB, increased preoperative fibrinogen concentration could serve as a valuable predictor for composite of morbidity endpoints, whereas low fibrinogen concentration was not found to be a risk factor of bleeding. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1661~1666 | - |
dc.relation.isPartOf | CIRCULATION JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Blood Loss, Surgical/mortality | - |
dc.subject.MESH | Blood Loss, Surgical/prevention & control* | - |
dc.subject.MESH | Coronary Artery Bypass, Off-Pump* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fibrinogen/metabolism* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Myocardial Infarction/blood | - |
dc.subject.MESH | Myocardial Infarction/etiology | - |
dc.subject.MESH | Myocardial Infarction/mortality | - |
dc.subject.MESH | Platelet Aggregation Inhibitors/administration & dosage* | - |
dc.subject.MESH | Platelet Aggregation Inhibitors/adverse effects | - |
dc.subject.MESH | Preoperative Care* | - |
dc.subject.MESH | Preoperative Period* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Ticlopidine/administration & dosage | - |
dc.subject.MESH | Ticlopidine/adverse effects | - |
dc.subject.MESH | Ticlopidine/analogs & derivatives* | - |
dc.title | Impact of preoperative fibrinogen concentration on postoperative outcome in patients who received dual antiplatelet therapy in proximity to off-pump coronary bypass surgery | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Anesthesiology (마취통증의학) | - |
dc.contributor.googleauthor | Na Young Kim | - |
dc.contributor.googleauthor | Jae-Kwang Shim | - |
dc.contributor.googleauthor | Jong Wook Song | - |
dc.contributor.googleauthor | Eui-Kyung Kim | - |
dc.contributor.googleauthor | Young-Lan Kwak | - |
dc.identifier.doi | 10.1253/circj.CJ-14-0161 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00172 | - |
dc.contributor.localId | A02060 | - |
dc.contributor.localId | A02205 | - |
dc.contributor.localId | A00348 | - |
dc.relation.journalcode | J00534 | - |
dc.identifier.eissn | 1347-4820 | - |
dc.identifier.pmid | 24739221 | - |
dc.subject.keyword | Antiplatelet therapy | - |
dc.subject.keyword | Coronary artery bypass | - |
dc.subject.keyword | Fibrinogen | - |
dc.subject.keyword | Outcome | - |
dc.contributor.alternativeName | Kwak, Young Lan | - |
dc.contributor.alternativeName | Kim, Na Young | - |
dc.contributor.alternativeName | Song, Jong Wook | - |
dc.contributor.alternativeName | Shim, Jae Kwang | - |
dc.contributor.affiliatedAuthor | Kwak, Young Lan | - |
dc.contributor.affiliatedAuthor | Song, Jong Wook | - |
dc.contributor.affiliatedAuthor | Shim, Jae Kwang | - |
dc.contributor.affiliatedAuthor | Kim, Na Young | - |
dc.citation.volume | 78 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1661 | - |
dc.citation.endPage | 1666 | - |
dc.identifier.bibliographicCitation | CIRCULATION JOURNAL, Vol.78(7) : 1661-1666, 2014 | - |
dc.identifier.rimsid | 54306 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.